Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center
Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research...
ADC / XDC
AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for...
Boan Biotech Secures FDA Orphan Drug Designations for Two Claudin18.2 Targeting Candidates
Boan Biotech (HKG: 6955), a Chinese biotechnology company, has announced that it has received orphan...
Merck’s Bavencio Shows Promising Survival Data in Real-World Urothelial Carcinoma Studies
German pharmaceutical company Merck (NYSE: MRK) has released data from real-world studies for its anti-PD-L1...
WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial
Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...
USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo
In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...
RemeGen’s MSLN-Targeted ADC RC88 Clears to Begin Phase I/IIa Study in China
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a leading Chinese biotech firm, has announced that...
RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer
China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...
BioNTech Acquires Pre-Clinical Asset and ADC Technology from Portuguese Biotech CellmAbs
Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC)...
Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration
The US Food and Drug Administration (FDA) has accepted for priority review a filing from...
OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study
OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from...
Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to...
Allist Pharmaceuticals’ Furmonertinib and AstraZeneca’s Enhertu Earn Breakthrough Designations in China for NSCLC Treatments
The Center for Drug Evaluation (CDE) in China has indicated on its website that Allist...
Hengrui Pharmaceuticals Gets NMPA Green Light for Phase Ib/II Study of SHR-A1921 Combo in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Biocytogen Strikes Exclusive Licensing Deal with US-Based Radiance Biopharma for Innovative BsADC
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a leading biopharmaceutical company based in China ,...
MSD Advances Four Oncology Candidates to Late-Stage Trials, Including Partnerships with Kelun-Biotech and Orion
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced significant progress in its oncology pipeline...
OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC
OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising...
WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC
Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...